This Day On The Street
Continue to site
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Thursday's Health Winners & Losers

Updated from 12:51 p.m. EDT

Earnings beats and positive news out of Amgen (AMGN - Get Report) were supporting the health care sector Thursday, even as the major markets were sliding.

Amgen said Thursday that its Aranesp anemia drug was not contributing to the deaths of patients in a Phase III lung cancer trial. The biotech giant added $2.31, or 3.6%, to $62.32.

Gilead Sciences (GILD - Get Report) reported a 55% jump in first-quarter earnings from a year ago, topping Wall Street's consensus forecast. Gilead was higher by $3.28, or 4.2%, at $81.71.

Both Amgen and Gilead are components of the Amex Biotechnology Index, but their gains merely buoyed the index's gain of 0.7%.

Among others reporting earnings, Dow Jones Industrial Average component Merck (MRK) posted first-quarter earnings that were in line with estimates. Meanwhile, Schering-Plough (SGP) topped estimates.

The Amex Pharmaceutical Index, of which both are components, was higher by 0.9%.

Among other winners, Monogram Biosciences (MGRM) soared 9.5% to $2.08. Arena Pharmaceuticals (ARNA - Get Report), which posted a widening first-quarter loss that was still better than the Thomson First Call average estimate, was higher by 7.9% at $12.25. St. Jude Medical (STJ) rose 5.5% after raising its full-year outlook.

Decliners included UnitedHealth (UNH - Get Report), which beat estimates and guided in line for the second quarter and full year. Despite the positive news, the stock lost $2.16, or 4%, to $52.05.

1 of 2

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Submit an article to us!
SYM TRADE IT LAST %CHG
ARNA $4.34 0.00%
AMGN $160.36 0.00%
GILD $105.01 0.00%
SYK $93.40 0.00%
UNH $113.20 0.00%

Markets

DOW 18,024.06 +183.54 1.03%
S&P 500 2,108.29 +22.78 1.09%
NASDAQ 5,005.3910 +63.9670 1.29%

Partners Compare Online Brokers

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs